Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Gritstone bio Inc. (GRTS : NSDQ)
 
 • Company Description   
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.

Number of Employees: 193

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.95 Daily Weekly Monthly
20 Day Moving Average: 1,188,551 shares
Shares Outstanding: 72.81 (millions)
Market Capitalization: $141.99 (millions)
Beta: 0.67
52 Week High: $14.42
52 Week Low: $1.82
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -38.49% -30.71%
12 Week -60.76% -56.86%
Year To Date -84.84% -81.47%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
5959 HORTON STREET SUITE 300
-
EMERYVILLE,CA 94608
USA
ph: 510-871-6100
fax: -
ir@gritstone.com http://www.gritstoneoncology.com
 
 • General Corporate Information   
Officers
Andrew Allen - President; Chief Executive Officer and Director
Elaine Jones - Chairperson
Vassiliki Economides - Chief Financial Officer
James Cho - Chief Accounting Officer
Clare Fisher - Director

Peer Information
Gritstone bio Inc. (CORR.)
Gritstone bio Inc. (RSPI)
Gritstone bio Inc. (CGXP)
Gritstone bio Inc. (BGEN)
Gritstone bio Inc. (GTBP)
Gritstone bio Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 39868T105
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 72.81
Most Recent Split Date: (:1)
Beta: 0.67
Market Capitalization: $141.99 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.40 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.51 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.75
Price/Cash Flow: -
Price / Sales: 9.04
EPS Growth
vs. Year Ago Period: -440.00%
vs. Previous Quarter: 5.56%
Sales Growth
vs. Year Ago Period: -81.88%
vs. Previous Quarter: 134.69%
ROE
03/31/22 - -56.52
12/31/21 - -37.44
09/30/21 - -38.51
ROA
03/31/22 - -44.02
12/31/21 - -29.43
09/30/21 - -30.07
Current Ratio
03/31/22 - 5.65
12/31/21 - 5.52
09/30/21 - 6.01
Quick Ratio
03/31/22 - -
12/31/21 - 5.52
09/30/21 - 6.01
Operating Margin
03/31/22 - -712.33
12/31/21 - -155.73
09/30/21 - -155.88
Net Margin
03/31/22 - -712.33
12/31/21 - -155.73
09/30/21 - -155.88
Pre-Tax Margin
03/31/22 - -712.33
12/31/21 - -155.73
09/30/21 - -155.88
Book Value
03/31/22 - 2.60
12/31/21 - 3.18
09/30/21 - 3.06
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©